Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part B Drugs At Home: Medicare Policy Responds To COVID-Driven Access Concerns

Executive Summary

Temporary policy may open door to longer term change as Medicare allows reimbursement of at-home administration of non-hospital drugs covered by Part B under a recently-released regulation aiding at encouraging telehealth during the coronavirus outbreak.

You may also be interested in...



Medicare Pressed To Expand Home Infusion Emergency Access Plan Even Further

Plan to allow broader coverage for home infused drugs during the COVID-19 emergency prompts opposition from providers seeking an approach more in line with commercial insurance practices.

Medicare Will Boost Physician Reimbursement For Sharing COVID-19 Clinical Trial Data

Participants in CMS's Quality Payment Program can earn credit to boost their Medicare reimbursements by reporting information from COVID-19 drug trials through a clinical trial repository or registry; NIH issues treatment guidelines for the coronavirus that are to be continuously updated.

Drug Coverage In The Pandemic: US Payers Shift Focus From Costs To Access, For Now

Payer concessions to ensure access to drugs during the COVID-19 outbreak offer a benefit to patients and biopharma. But the costs involved could intensify future efforts to manage drug spending.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS141990

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel